1493 related articles for article (PubMed ID: 26193796)
21. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
22. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
Zelickson BD; Peters MS; Muller SA; Thibodeau SN; Lust JA; Quam LM; Pittelkow MR
J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):787-96. PubMed ID: 1839392
[TBL] [Abstract][Full Text] [Related]
23. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
24. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
26. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
27. [Angioimmunoblastic lymphadenopathy and angioimmunoblastic T-cell lymphoma].
Li T; Gao D; Zhang B
Zhonghua Bing Li Xue Za Zhi; 1996 Apr; 25(2):99-101. PubMed ID: 9206215
[TBL] [Abstract][Full Text] [Related]
28. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
[TBL] [Abstract][Full Text] [Related]
31. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
32. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
33. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
Smith BD; Wilson LD
Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
[TBL] [Abstract][Full Text] [Related]
34. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
35. Dermatopathic lymphadenopathy. An immunophenotypic comparison of cases associated and unassociated with mycosis fungoides.
Burke JS; Sheibani K; Rappaport H
Am J Pathol; 1986 May; 123(2):256-63. PubMed ID: 3486598
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of cutaneous T-cell lymphoma.
Abel EA
Dermatol Clin; 1985 Oct; 3(4):647-64. PubMed ID: 2878755
[TBL] [Abstract][Full Text] [Related]
37. Blood and lymph node T lymphocytes in cutaneous T cell lymphoma: evaluation by light microscopy.
Schechter GP; Bunn PA; Fischmann AB; Matthews MJ; Guccion J; Soehnlen F; Munson D; Minna JD
Cancer Treat Rep; 1979 Apr; 63(4):571-4. PubMed ID: 312694
[TBL] [Abstract][Full Text] [Related]
38. [Lymph node histopathologic aspects in cutaneous lymphomas of the mycosis fungoides or Sézary syndrome type. Retrospective study of 98 biopsies].
Wechsler J; Diebold J; Gerard-Marchant R
Ann Pathol; 1987; 7(2):122-9. PubMed ID: 3620027
[TBL] [Abstract][Full Text] [Related]
39. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
40. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
